|
Characteristic
|
Uterine cancer (N = 53)
|
|---|
|
Pre-op Histology (n = 49)
|
|
Endometrioid
|
34 (69.4)
|
|
Serous
|
6 (12.2)
|
|
Clear cell
|
3 (6.1)
|
|
Carcinosarcoma
|
3 (6.1)
|
|
Other/unspecified
|
7 (14.3)
|
|
Post-op Histology
|
|
Endometrioid
|
40 (75.5)
|
|
Serous
|
5 (9.4)
|
|
Clear cell
|
1 (1.9)
|
|
Carcinosarcoma
|
7 (13.2)
|
|
Grade
|
|
1
|
21 (39.6)
|
|
2
|
15 (28.3)
|
|
3
|
17 (32.1)
|
|
Stage
|
|
IA
|
28 (52.8)
|
|
IBa
|
15 (28.3)
|
|
II
|
1 (1.9)
|
|
IIIA
|
2 (3.8)
|
|
IIIC1
|
3 (5.7)
|
|
IIIC2
|
2 (3.8)
|
|
IVB
|
2 (3.8)
|
|
Lymph nodes
|
|
Positive
|
6 (11.32)
|
|
Negative
|
29 (54.7)
|
|
Not collected
|
18 (34.0)
|
|
Pelvic Washings
|
|
Positive
|
5 (9.4)
|
|
Negative
|
41 (77.4)
|
|
Indeterminate/suspicious
|
6 (11.3)
|
|
Not collected
|
1 (1.9)
|
|
Adjuvant Therapyb
|
|
Radiation
|
13 (24.5)
|
|
Chemotherapy
|
10 (18.9)
|
|
Hormonal
|
4 (7.6)
|
|
Recurrence rate
|
7 (13.2)
|
|
Median time to recurrence (days)
|
395 [range 128–539]
|
|
Status of disease
|
|
No evidence of disease
|
43 (81.1)
|
|
Alive with diseasec
|
3 (5.7)
|
|
Died of disease
|
5 (9.4)
|
|
Died of intercurrent disease
|
1 (1.9)
|
|
Died of unknown caused
|
1 (1.9)
|
- Data are n(%) unless otherwise specified
- aDepth of invasion could not be determined in one case and is included in the Stage 1B group
- bChemotherapy: Carboplatin/Taxol (6), Carboplatin/Taxol + Cisplatin (with radiation) (1), Carboplatin/Taxol + Doxil (1); Ifosfamide/Taxol (2). Radiation: vaginal brachytherapy (5), external beam radiation (4), IMRT (2), vaginal brachytherapy + external beam radiation (1). Hormonal: Megace (2), Megace + Tamoxifen (1), Megace + Anastrozole (1)
- c(1) IIIC-2, grade 2 endometrioid, disease-free survival 7.8 months (2) IA, grade 2 endometrioid, disease-free survival 13.2 months (3) IB, grade 3 endometrioid, disease-free survival 4.3 months
- dMost likely this patient died of disease given her disease distribution with distant metastases
